Brief: Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors
30/06/2025 13:15
Revolution Medicines Inc RVMD.O: REVOLUTION MEDICINES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF THREE RAS(ON) INHIBITORS WITH IVONESCIMAB IN RAS MUTANT TUMORS REVOLUTION MEDICINES INC - SUMMIT TO SUPPLY IVONESCIMAB, REVOLUTION MEDICINES TO SPONSOR STUDY Source text: ID:nGNX8PWjNv Further company coverage: RVMD.O
Recent news on Summit Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Intel, Victoria's Secret, Super Micro
U.S. STOCKS ON THE MOVE-Novo Nordisk, Intel, Oracle
Summit Therapeutics rebounds after pulling stock offering
Brief: Summit Therapeutics Withdraws Proposed Underwritten Public Offering Effective- SEC Filing
Summit Therapeutics falls on launching $500 mln stock offering